Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Jul 12, 2022 Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health Jun 30, 2022 Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO Jun 28, 2022 Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi® Jun 2, 2022 US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years May 20, 2022 Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering May 19, 2022 Evofem Biosciences Announces Proposed Public Offering May 10, 2022 Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi® May 6, 2022 Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial May 5, 2022 Evofem Biosciences Announces 1-for-15 Reverse Stock Split May 4, 2022 Evofem Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update Show 5102550100 per page«1…45678910…24»
